Abstracts tagged "Opioids and rheumatoid arthritis (RA)"

Abstract Number: 199 • 2019 ACR/ARP Annual Meeting
Obesity and Incident Opioid Use in Rheumatoid Arthritis
Joshua Baker¹, Sofia Pedro ² and Kaleb Michaud ³, ¹University of Pennsylvania, Philadelphia, PA, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Prevalent chronic use of opioids approximately 17% among patients with rheumatoid arthritis (RA) and has increased over the last decade.(1) Obesity may be a…
Abstract Number: 2783 • 2017 ACR/ARHP Annual Meeting
Medications Associated with Osteoporotic Fracture Risk in Patients with Rheumatoid Arthritis
Gulsen Ozen¹, Sofia Pedro², Frederick Wolfe² and Kaleb Michaud¹, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Osteoporotic (OP) fractures are a major cause of disability, cost, and mortality in RA. Besides increased OP fracture risk, chronic inflammation and pain predispose…
Abstract Number: 3086 • 2016 ACR/ARHP Annual Meeting
Changing Patterns over Time in Opiate Use in U.S. Rheumatoid Arthritis Patients
Jeffrey Curtis¹, Fenglong Xie², Kenneth Saag³, Lang Chen², Timothy Beukelman⁴, Melissa Mannion⁵ and Huifeng Yun⁶, ¹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatric Rheumatology, University of Alabama-Birmingham, Birmingham, AL, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Opiate use has come under increasing scrutiny related both to over-use and under-use. The patterns of opiate use over time in a population-based cohort…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.